Laurus Labs

Eight Roads Ventures China Promotes Three New Partners Further Strengthening its Leadership Team

Retrieved on: 
Wednesday, February 15, 2023
Artificial intelligence, Augmented reality, Contract research organization, Deep tech, Gravity, Investment, VR, Marketing, Virtual reality, HR, Fintech, PharmEasy, Associate, Gordon, Tech, Software, IQVIA, AppsFlyer, Accounting, RMB, Laurus Labs, Ali Baba, Shawn, Build automation, Lightspeed Venture Partners, Partner, Fidelity, Digital health, JBD, AR, CXO, Mining, Video game, Asset management, Cryptocurrency, Neo4j, China Venture Capital Association, Metaverse, Novus Inceptio, Table tennis, Samsung Strategy and Innovation Center

Despite the market volatility, Eight Roads has continued to grow its team in China over the past 12 months, showcasing the strength and benefits of having proprietary and patient capital of Fidelity.

Key Points: 
  • Despite the market volatility, Eight Roads has continued to grow its team in China over the past 12 months, showcasing the strength and benefits of having proprietary and patient capital of Fidelity.
  • After the promotion, Eight Roads Ventures China has 10 Partners across its healthcare and technology teams, and each of them brings an average of 20 years of experience from China and abroad.
  • "We are delighted to welcome Shawn, Cody and Gordon to the leadership team in China," said, Jarlon Tsang, Managing Partner and Head of China at Eight Roads Ventures.
  • Since joining the firm's technology team in 2014, Gordon invests in fintech, software, smart manufacturing and blockchain sectors in China.

GMP Cell Therapy Consumables Global Market Report 2022: Increasing Popularity of Strategic Collaborations Spurs Growth - ResearchAndMarkets.com

Retrieved on: 
Tuesday, January 3, 2023
Biotechnology, Health, Genetics, Pharmaceutical, Clinical Trials, QC, CPAS, IPSC, Lisocabtagene maraleucel, CGMP-specific phosphodiesterase type 5, GMP, Sartorius, Food, Drug discovery, Therapy, Research, Quality control, COVID-19, CGT, Cryopreservation, Growth, Patient, CGMP, US Foods, FDA, Process, Laurus Labs, Food and Drug Administration, Workflow, Implant, Cell, Pharmaceutical industry, Fine chemical, Vaccine

The "GMP Cell Therapy Consumables Market Forecast to 2028 - COVID-19 Impact and Global Analysis by Product, Cell Therapy, Process, and End Use" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "GMP Cell Therapy Consumables Market Forecast to 2028 - COVID-19 Impact and Global Analysis by Product, Cell Therapy, Process, and End Use" report has been added to ResearchAndMarkets.com's offering.
  • Also, the increasing use of cell therapy to treat various diseases is propelling the demand for cell therapy consumables manufactured according to GMP regulations.
  • The companies in the GMP cell therapy consumables market is making strategic collaborations for the development of new products and cell therapy treatments.
  • The increase in strategic collaborations among market players for cell therapy development has propelled the use of GMP cell therapy consumables to achieve the desired products, which drives the growth of the GMP cell therapy consumables market.

Elucidata Raises $16 Million Series A to Reimagine AI Infrastructure for the Life Sciences Industry

Retrieved on: 
Tuesday, September 27, 2022
Cygnus, TB, Health, D, Internet, Fidelity, MIT, Therapy, IIT, Eight Roads Ventures, Bill & Melinda Gates Foundation, History, Laurus Labs, CEO, Organization, Technology, Stanford University, Spry, IIT Delhi, Polly, US, Failure, GUI, Heart, Data science, Janssen, R, Multimedia, Genentech, AI, University, Drug discovery, University of Chicago, Medical device, Fine chemical, Pfizer

Elucidata's platform Polly, enables pharmaceutical and diagnostic companies to adopt a data-centric approach for successful AI/ML initiatives.

Key Points: 
  • Elucidata's platform Polly, enables pharmaceutical and diagnostic companies to adopt a data-centric approach for successful AI/ML initiatives.
  • Used by leading life sciences companies on over 2.5 million biomolecular datasets, Polly leverages proprietary Bio-NLP technology to rapidly curate biomedical data with human-levels of accuracy, making it machine learning-ready (ML-ready).
  • Elucidata sees the era of AI as one in which life sciences companies leverage the benefits of AI.
  • In May this year, Eight Roads launched its first dedicated US$250 million healthcare and life sciences fund for India.

Health Tech Start-up Spry Secures New Investment to Further Strengthen Its Omnichannel Patient Management Platform for Physical Therapists

Retrieved on: 
Wednesday, June 22, 2022
Solution, Practice management, List of life sciences, Ola, Technology, CEO, EMR, Centers for Medicare & Medicaid Services, Adoption, Medicare, Therapy, Fidelity, Eight Roads Ventures, Laurus Labs, Partnership, History, Patient, Communication, Riyaz, Health, Movement, Multimedia, Center, Medicine, Hospital, Health insurance, Online shopping, Spry, Brijraj Singh

DELAWARE, June 22, 2022 /PRNewswire/ -- Spry, an end-to-end patient and practice management SaaS platform for physical therapists, today announced that it has successfully completed a new round of funding to accelerate its mission to build the future of practice management for physical rehabilitation. With this new round, the company has raised over US $10 million to date. The round was led by Eight Roads Ventures, with participation from F-Prime Capital and existing investor, Together Fund.

Key Points: 
  • "With our 25 member strong team, we have been able to build a new-age, reliable andtrustworthy platform to enable physical therapists to manage an omnichannel practice andimprove the quality of patient care.
  • Founded in 2021 by Ola's former chief technology officer, Brijraj Bhuptani, and RiyazRehman, Spry aims to democratize the accessibility and affordability of movement healththrough its full-stack digital health platform.
  • Theplatform supports a clinic's end-to-end operations, from patient intake to scheduling, communication, assessments, electronic medical records ('EMR'), revenue cyclemanagement,homeexerciseplans,adherencetracking andpatientlifecycle management.
  • Many physical therapists arealso setting up their own private practices, giving them increased autonomy and the ability topersonalizetreatment.

Doceree Closes $11 Million Series A Funding Round Led by Eight Roads Ventures

Retrieved on: 
Thursday, April 7, 2022
Cygnus, HCP, Winfield F. Prime, Harshit Saxena, UK, Europe and Africa Malankara Orthodox Diocese, Behavior, Partnership, Growth, UK, Eight Roads Ventures, History, Prescription, Communication, Health, Industry, Technology, Knowledge, Laurus Labs, Ecosystem, Fidelity, Physician, Solution, HCPS, Patient, Financial services, Public relations, Fine chemical, Online shopping, EU

PARSIPPANY, N.J., April 6, 2022 /PRNewswire/ -- Doceree Inc, the first global network of physician-only platforms for programmatic messaging, today announced the completion of $11 million Series A funding round led by Eight Roads Ventures, a global investment firm backed by Fidelity. F-Prime Capital and Alkemi Growth Capital also participated in the round. 

Key Points: 
  • PARSIPPANY, N.J., April 6, 2022 /PRNewswire/ --Doceree Inc, the first global network of physician-only platforms for programmatic messaging, today announced the completion of $11 million Series A funding round led by Eight Roads Ventures, a global investment firm backed by Fidelity.
  • Currently, Doceree is working with eight of the top 10 global pharma brands and the company currently engages more than 1 million HCPs across the globe.
  • "Doceree is transforming the way digital interactions between pharmaceutical brands and prescribers are facilitated," says Ashish Venkataramani, Partner, Eight Roads Ventures.
  • "Doceree has proven the ability to efficiently connect stakeholders and is well-positioned to serve the needs of the pharma industry."

NOCD Raises $33 Million to Address Global OCD Crisis; Series B Financing to Support People Struggling with OCD, Fuel Growth

Retrieved on: 
Tuesday, September 21, 2021
Data Management, Insurance, Other Health, Technology, Managed Care, Professional Services, Mental Health, Women, Hospitals, Men, Clinical Trials, Family, Software, Alternative Medicine, Consumer, Health, Neo4j, Fidelity, Hope, Xoom, Therapy, Health, Mark (given name), Telehealth, Patient, Precision medicine, OCD, ERP, Kaiser Permanente, University of Florida Obsessive Compulsive Disorder Program, PHP, Wuxi, CA, Life, Growth, Eight Roads Ventures, Hearing, Technology, Ali Baba, AppsFlyer, Capital, Laurus Labs, Traction, Duck, Nike Flywire, Lists of diseases, History, IOP, Response, Pony.ai, Medtech, HEP, Anxiety, Hoard, Health insurance, Financial services, Healthcare, Hospital, Medicine, Pharmaceutical industry

NOCD, for the first time, offers an accessible and effective solution for one of the most prevalent and stigmatized behavioral health populations people with OCD.

Key Points: 
  • NOCD, for the first time, offers an accessible and effective solution for one of the most prevalent and stigmatized behavioral health populations people with OCD.
  • We look forward to working with our investors who participated in this financing to accelerate our mission to improve the lives of people with OCD and support our significant growth.
  • Inside the NOCD platform, members can receive ongoing, face-to-face telehealth sessions from licensed NOCD therapists that specifically specialize in OCD treatment.
  • Were excited to support NOCD as the platform scales to address the needs of millions suffering from OCD.